Prognostic value of the expression of epithelial cell adhesion molecules in head and neck squamous cell carcinoma treated by definitive radiotherapy

J Radiat Res. 2019 Nov 22;60(6):803-811. doi: 10.1093/jrr/rrz053.

Abstract

A reliable biomarker can contribute to appropriate treatment selection in the management of head and neck squamous cell carcinoma (HNSCC). Recently, epithelial cell adhesion molecule (EpCAM) was shown to have prognostic features in several malignancies. However, it remains to be elucidated whether EpCAM predicts prognosis of HNSCC after radiotherapy. Therefore, the prognostic potential of EpCAM in HNSCC patients treated by radiotherapy was investigated in this study. All HNSCCs patients examined between January 2013 and December 2015 were analyzed for the expression of EpCAM. One hundred HNSCC patients were identified who were treated by primary radiotherapy. Intense expression of EpCAM was found in 29 HNSCC patients. Two-year overall survival (OS) for patients with intense EpCAM expression was 62.2%, whereas it was 87.9% for those without (P = 0.011). In multivariate analysis, intense EpCAM expression was found to be an independent prognostic factors for OS (P = 0.036). Overall, EpCAM was found to be an independent prognostic factor for HNSCC.

Keywords: BerEP4; EpCAM; biomarker; head and neck squamous cell carcinoma; primary radiation therapy.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Cyclin-Dependent Kinase Inhibitor p16 / metabolism
  • Disease-Free Survival
  • Epithelial Cell Adhesion Molecule / metabolism*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Prognosis
  • Proportional Hazards Models
  • Squamous Cell Carcinoma of Head and Neck / metabolism*
  • Squamous Cell Carcinoma of Head and Neck / pathology
  • Squamous Cell Carcinoma of Head and Neck / radiotherapy*
  • Young Adult

Substances

  • Cyclin-Dependent Kinase Inhibitor p16
  • Epithelial Cell Adhesion Molecule